Connecting via Winsock to STN

LOGINID:
SSPTAEAL1624

STNLOGON timed out

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment

```
 NEWS 26  DEC 17  MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
 NEWS 27  DEC 17  CA/CAplus enhanced with new custom IPC display formats
 NEWS 28  DEC 17  STN Viewer enhanced with full-text patent content
                  from USPATOLD
 NEWS 29  JAN 02  STN pricing information for 2008 now available

 NEWS EXPRESS   19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
                CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
                AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:12:09 ON 15 JAN 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 18:12:52 ON 15 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 JAN 2008  HIGHEST RN 960583-85-1
DICTIONARY FILE UPDATES:  14 JAN 2008  HIGHEST RN 960583-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html
```

=>
Uploading C:\Program Files\Stnexp\Queries\10561747.str





chain nodes :
7 8 9 10 11 12 13 14 15 16 17 19 20 21 23 24 25 26 27 28 29 30
31 32 33 34
ring nodes :
1 2 3 4 5 6
chain bonds :
1-29 1-30 2-20 3-31 3-32 4-33 4-34 5-7 6-27 6-28 7-8 7-16 7-17 8-9
8-24 8-25 9-10 9-19 9-26 10-11 10-14 11-12 11-13 14-15 20-21 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 2-20 3-4 4-5 5-6 5-7 7-8 7-16 7-17 9-10 9-19 10-11 10-14
11-12 20-21 21-23
exact bonds :
1-29 1-30 3-31 3-32 4-33 4-34 6-27 6-28 8-9 8-24 8-25 9-26 11-13 14-15

isolated ring systems :
containing 1 :

G1:Cy,Ak

G2:Cb,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS
20:Atom 21:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

L1 STRUCTURE UPLOADED

=> s l1 fulll
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms. L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles. The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> s l1 full
FULL SEARCH INITIATED 18:13:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 837 TO ITERATE

100.0% PROCESSED 837 ITERATIONS 51 ANSWERS
SEARCH TIME: 00.00.01

L2 51 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 18:13:55 ON 15 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Jan 2008 VOL 148 ISS 3
FILE LAST UPDATED: 14 Jan 2008 (20080114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2 full
L3 3 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:630134 CAPLUS
DOCUMENT NUMBER: 145:103718
TITLE: Preparation of (piperazinylsulfonylmethyl)alkynyl hydroxamates and analogs as matrix metalloprotease inhibitors and medical uses thereof
INVENTOR(S): Swinnen, Dominique; Bombrun, Agnes; Gerber, Patrick; Jorand-Lebrun, Catherine
PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006067114	A1	20060629	WO 2005-EP56910	20051219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005318163	A1	20060629	AU 2005-318163	20051219
CA 2589367	A1	20060629	CA 2005-2589367	20051219
EP 1828160	A1	20070905	EP 2005-826371	20051219
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
KR 2007095950	A	20071001	KR 2007-716256	20070716
PRIORITY APPLN. INFO.:			EP 2004-106814 A	20041221
			US 2004-638257P P	20041222
			WO 2005-EP56910 W	20051219
OTHER SOURCE(S):	MARPAT 145:103718			

GI



I



II

AB Title compds. I [wherein A, B = (un)substituted CH2; R1 = (hetero)aryl or (hetero)cycloalkyl; R2 = H, alkyl, alkenyl or alkynyl; R3 = H, alkyl, (hetero)aryl, etc.; X = C, CH or N; Y = CH, CH2, -C=CH-, etc.; m = 0-2, n = 0-1; p = 1-2] and stereoisomers or pharmaceutically acceptable salts thereof were prepared as matrix metalloprotease (MMP) inhibitors. Some related intermediates were claimed. For instance, successive lithiation of 1-(4-fluorophenyl)-4-(methylsulfonyl)piperazine with lithium bis(trimethylsilyl)amide, reaction with di-Et chlorophosphate, olefination with 3-(1,3-Benzodioxol-5-yl)-2-propynal (69% yield for three steps), nucleophilic addition of the resultant α,β-unsatd. sulfone with hydroxylamine (81% yield), and N-formylation with formic acetic anhydride generated in situ from acetic anhydride and formic acid (50% yield) gave hydroxamate II. This product showed inhibition against MMP-1 and MMP-12 with IC50 values of > 5000 nM and 46 nM, resp. Other biol. activities were also disclosed. Therefore, I and their pharmaceutical compns. are useful for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis.

IT 895573-30-5P 895573-54-3P 895573-58-7P
895573-63-4P 895573-92-9P 895573-94-1P
895574-00-2P 895574-01-3P 895574-08-0P
895574-16-0P 895574-21-7P 895574-24-0P
895574-30-8P 895574-31-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (piperazinylsulfonylmethyl)alkynyl hydroxamates and analogs as matrix metalloprotease inhibitors and medical uses thereof)

RN 895573-30-5 CAPLUS

CN Piperazine, 1-[[2-(formylhydroxyamino)-3-nonynyl]sulfonyl]-4-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 895573-54-3 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-(3-pyridinyl)-3-butynyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895573-58-7 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-(3-methoxyphenyl)-3-butynyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895573-63-4 CAPLUS
CN Piperazine, 1-[[5-(diethylamino)-2-(formylhydroxyamino)-3-pentynyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895573-92-9 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-phenyl-3-butynyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895573-94-1 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-3-nonynyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895574-00-2 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-3-nonynyl]sulfonyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895574-01-3 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-3-nonynyl]sulfonyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895574-08-0 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-3-nonynyl]sulfonyl]-4-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895574-16-0 CAPLUS
CN Piperazine, 1-(4-ethoxyphenyl)-4-[[2-(formylhydroxyamino)-3-nonynyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 895574-21-7 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-phenyl-3-butynyl]sulfonyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895574-24-0 CAPLUS

CN Piperazine, 1-(4-ethoxyphenyl)-4-[[2-(formylhydroxyamino)-4-phenyl-3-butynyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 895574-30-8 CAPLUS
CN Piperazine, 1-(4-ethoxyphenyl)-4-[[2-(formylhydroxyamino)-3,3-dimethyl-6-phenyl-5-hexynyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 895574-31-9 CAPLUS
CN Piperazine, 1-(3,4-dimethoxyphenyl)-4-[[2-(formylhydroxyamino)-3-nonynyl]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:14380 CAPLUS
DOCUMENT NUMBER: 142:114099
TITLE: Preparation of N-[(4-substituted piperazine-1-sulfonylmethyl)alkyl]-N-hydroxyformamides as metalloproteinase inhibitors
INVENTOR(S): Finlay, Maurice Raymond Verschoyle; Waterson, David
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000822	A1	20050106	WO 2004-GB2702	20040623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004251104	A1	20050106	AU 2004-251104	20040623
CA 2529468	A1	20050106	CA 2004-2529468	20040623
EP 1644340	A1	20060412	EP 2004-743053	20040623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1812974	A	20060802	CN 2004-80018244	20040623
BR 2004011929	A	20060815	BR 2004-11929	20040623
JP 2007516164	T	20070621	JP 2006-516467	20040623
MX 2005PA13460	A	20060309	MX 2005-PA13460	20051209
US 2007197542	A1	20070823	US 2005-561747	20051221
NO 2006000444	A	20060322	NO 2006-444	20060127
PRIORITY APPLN. INFO.:			SE 2003-1922 A	20030627
			WO 2004-GB2702 W	20040623

OTHER SOURCE(S): MARPAT 142:114099
GI



I



II

AB The title compds. I [ring B = monocyclic aryl ring having six ring atoms or a monocyclic heteroaryl ring having up to six ring atoms and containing one or more ring heteroatoms wherein each said heteroatom is nitrogen; R2 = alkyl or aryl, which said group is substituted by one or more fluorine groups; n = 1-3; R1 = (un)substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyl-aryl, alkyl-heteroaryl, alkyl-cycloalkyl or alkyl-heterocycloalkyl], useful in the treatment of a disease condition mediated by one or more metalloproteinase enzymes, were prepared E.g., a multi-step synthesis of (S)-II, starting from 5-iodo-2-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine, was given. In general, the compds. I demonstrate IC50 values in the range of 0.01 to 1000 nM against collagenase 3. The pharmaceutical composition comprising the compound I is disclosed.

IT 823197-00-8P 823197-01-9P 823197-02-0P
823197-03-1P 823197-04-2P 823197-05-3P
823197-06-4P 823197-07-5P 823197-08-6P
823197-09-7P 823197-10-0P 823197-11-1P
823197-12-2P 823197-13-3P 823197-14-4P
823197-15-5P 823197-16-6P 823197-17-7P
823197-18-8P 823197-19-9P 823197-20-2P
823197-21-3P 823197-22-4P 823197-23-5P
823197-24-6P 823197-25-7P 823197-26-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[(4-substituted piperazine-1-sulfonylmethyl)alkyl]-N-hydroxyformamides as metalloproteinase inhibitors)

RN 823197-00-8 CAPLUS

CN Piperazine, 1-[[(2S)-2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-01-9 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 823197-02-0 CAPLUS
CN Piperazine, 1-[[4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 823197-03-1 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-2-(tetrahydro-2H-pyran-4-yl)ethyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 823197-04-2 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 823197-05-3 CAPLUS
CN Piperazine, 1-[[4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 823197-06-4 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-2-(tetrahydro-2H-pyran-4-yl)ethyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 823197-07-5 CAPLUS
CN Piperazine, 1-[[(2S)-2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-08-6 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 823197-09-7 CAPLUS
CN Piperazine, 1-[[(2S)-2-(formylhydroxyamino)-2-(tetrahydro-2H-pyran-4-yl)ethyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-10-0 CAPLUS

CN Piperazine, 1-[[2-(formylhydroxyamino)-2-phenylethyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-11-1 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-12-2 CAPLUS
CN Piperazine, 1-[[(2S)-2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-13-3 CAPLUS
CN Piperazine, 1-[[4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-14-4 CAPLUS
CN Piperazine, 1-[[(2S)-4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-15-5 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-16-6 CAPLUS
CN Piperazine, 1-[[(2S)-2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-17-7 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)butyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-18-8 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)propyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-19-9 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-20-2 CAPLUS
CN Piperazine, 1-[[(2S)-2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-21-3 CAPLUS
CN Piperazine, 1-[[4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-22-4 CAPLUS
CN Piperazine, 1-[[(2S)-4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-23-5 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-24-6 CAPLUS
CN Piperazine, 1-[[(2S)-2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-25-7 CAPLUS
CN Piperazine, 1-[[(2S)-2-(formylhydroxyamino)-2-(tetrahydro-2H-pyran-4-yl)ethyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-26-8 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:161258 CAPLUS
DOCUMENT NUMBER: 132:207849
TITLE: Preparation of arylpiperazines as metalloproteinase inhibiting agents (MMP)
INVENTOR(S): Barlaam, Bernard Christophe; Newcombe, Nicholas John; Tucker, Howard; Waterson, David
PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca-Pharma Sa
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012478	A1	20000309	WO 1999-GB2801	19990825
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339761	A1	20000309	CA 1999-2339761	19990825
AU 9955247	A	20000321	AU 1999-55247	19990825
AU 764367	B2	20030814		
BR 9913255	A	20010522	BR 1999-13255	19990825
EP 1109787	A1	20010627	EP 1999-941751	19990825
EP 1109787	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200100605	T2	20010821	TR 2001-605	19990825
HU 2001003344	A2	20020228	HU 2001-3344	19990825
HU 2001003344	A3	20020328		
EE 200100106	A	20020617	EE 2001-106	19990825
JP 2002523493	T	20020730	JP 2000-567511	19990825
NZ 509730	A	20030530	NZ 1999-509730	19990825
RU 2220967	C2	20040110	RU 2001-108591	19990825
NZ 524921	A	20041029	NZ 1999-524921	19990825
AT 326448	T	20060615	AT 1999-941751	19990825
PT 1109787	T	20060929	PT 1999-941751	19990825
ES 2263284	T3	20061201	ES 1999-941751	19990825
TW 240722	B	20051001	TW 1999-88114833	19990830
ZA 2001001231	A	20020513	ZA 2001-1231	20010213
MX 2001PA01847	A	20020408	MX 2001-PA1847	20010220
US 6734184	B1	20040511	US 2001-763709	20010226
KR 771454	B1	20071031	KR 2001-702457	20010226
NO 2001001023	A	20010425	NO 2001-1023	20010228
NO 321478	B1	20060515		
BG 105369	A	20011231	BG 2001-105369	20010322
HK 1036060	A1	20061027	HK 2001-106732	20010924
AU 2003262101	A1	20031218	AU 2003-262101	20031112
US 2004171641	A1	20040902	US 2004-787775	20040226
PRIORITY APPLN. INFO.:			EP 1998-402144 A	19980831

EP 1999-401351 A 19990604
WO 1999-GB2801 W 19990825
US 2001-763709 A1 20010226

OTHER SOURCE(S): MARPAT 132:207849

GI



I



II

AB The title compds. [I; B = monocyclic or bicyclic alkyl, aryl, etc.; R3 = H, halo, NO2. etc.; n = 1-3; P = (CH2)n (wherein n = 0-2), alkene, alkyne, etc.; A = (un)substituted 5-7 membered aliphatic ring; X1, X2 = N, C, where a ring substituent on ring A is a oxo group that is preferably adjacent a ring N atom; Y = SO2, CO; Z = CONHOH, Y = CO and Q = CR6R7, CR6R7CH2, NR6, NR6CH2 (wherein R6 = H, alkyl, aralkyl, etc.; R7 = H, alkyl; R7 together with R6 forms a carbocyclic or heterocyclic spiro 5-7 membered ring, the latter containing at least one heteroatom selected from N, O, S); Z = CONHOH, Y = SO2 and Q = CR6R7, CR6R7CH2; Z = N(OH)CHO and Q = CHR6, CHR6CH2, NR6CH2; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, aryl, etc.], useful as metalloproteinase inhibitors (no data), especially as inhibitors of MMP 13, in treating arthritis and atherosclerosis, were prepared E.g., a multi-step synthesis of the title piperazine II was given. Compds. I are effective at 0.5-30 mg/kg/day.

IT 260439-08-5P 260439-96-1P 260440-00-4P
260440-21-9P 260441-00-7P 260441-01-8P
260441-02-9P 260441-03-0P 260441-04-1P
260441-05-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpiperazines as metalloproteinase inhibiting agents (MMP))

RN 260439-08-5 CAPLUS

CN Piperazine, 1-[[2-(formylhydroxyamino)-4-phenylbutyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 260439-96-1 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-2-phenylethyl]sulfonyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 260440-00-4 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-2-phenylethyl]sulfonyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 260440-21-9 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-2-phenylethyl]sulfonyl]-4-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 260441-00-7 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-3-(phenylmethoxy)propyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 260441-01-8 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-(2-pyridinyl)butyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 260441-02-9 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-4-(3-pyridinyl)butyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 260441-03-0 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-5-(2-thienyl)pentyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 260441-04-1 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 260441-05-2 CAPLUS
CN Piperazine, 1-[[2-(formylhydroxyamino)-5-(2-pyridinyl)pentyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 18:12:09 ON 15 JAN 2008)

     FILE 'REGISTRY' ENTERED AT 18:12:52 ON 15 JAN 2008
L1             STRUCTURE UPLOADED
L2           51 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 18:13:55 ON 15 JAN 2008
L3            3 S L2 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    31.71     210.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -2.40      -2.40

STN INTERNATIONAL LOGOFF AT 18:33:01 ON 15 JAN 2008
```